Stock listing
NASDAQ:ANNX Annexon, Inc. Stock
Home listing (NASDAQ) of Annexon, Inc.
Follow Annexon, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ANNX
$3.10 USD -0.42 (-11.9%)
Close on Nov 20, 2026
- Day range
- $3.07 – $3.37 USDNov 20, 2026
- Volume
- 4.45M sharesNov 20, 2026
- Market cap
- $587.7M USDAt the close on Nov 20, 2026 · price × 189.6M shares outstanding
- 52-week range
- $3.07 – $7.18 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $13.55M USDMedian day 3.08M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ANNX · Home | $3.10 USD | -0.42 (-11.9%) | 4,454,126 | $3.37 | $3.37 | $3.07 | $3.52 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ANNX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.10 | -0.42 | -11.9% | $3.37 | $3.37 | $3.07 | 4,454,126 | |
| $3.52 | +0.05 | +1.4% | $3.46 | $3.63 | $3.44 | 2,975,857 | |
| $3.47 | -0.10 | -2.8% | $3.67 | $3.67 | $3.37 | 2,880,090 | |
| $3.57 | -0.35 | -8.9% | $3.90 | $3.975 | $3.55 | 3,113,341 | |
| $3.92 | -0.05 | -1.3% | $3.97 | $3.99 | $3.75 | 2,584,906 | |
| $3.97 | -0.22 | -5.3% | $4.14 | $4.17 | $3.87 | 4,462,474 | |
| $4.19 | -0.02 | -0.5% | $4.25 | $4.275 | $4.14 | 3,075,985 | |
| $4.21 | -0.02 | -0.5% | $4.30 | $4.37 | $4.105 | 4,596,063 | |
| $4.23 | +0.03 | +0.7% | $4.26 | $4.325 | $4.15 | 2,815,581 | |
| $4.20 | +0.195 | +4.9% | $4.05 | $4.29 | $4.04 | 2,621,896 | |
| $4.005 | -0.325 | -7.5% | $4.29 | $4.355 | $3.83 | 4,358,605 | |
| $4.33 | +0.14 | +3.3% | $4.255 | $4.52 | $4.155 | 4,432,604 | |
| $4.19 | +0.25 | +6.3% | $3.98 | $4.23 | $3.94 | 4,280,894 | |
| $3.94 | -0.11 | -2.7% | $4.06 | $4.08 | $3.90 | 2,276,667 | |
| $4.05 | +0.04 | +1.0% | $4.00 | $4.09 | $3.87 | 2,837,114 | |
| $4.01 | -0.03 | -0.7% | $4.04 | $4.20 | $3.95 | 3,284,752 | |
| $4.04 | +0.28 | +7.4% | $3.78 | $4.05 | $3.716 | 4,010,595 | |
| $3.76 | +0.06 | +1.6% | $3.72 | $3.835 | $3.68 | 2,964,361 | |
| $3.70 | -0.05 | -1.3% | $3.80 | $3.86 | $3.66 | 2,647,455 | |
| $3.75 | -0.06 | -1.6% | $3.78 | $3.85 | $3.64 | 2,575,383 | |
| $3.81 | -0.05 | -1.3% | $3.85 | $3.97 | $3.78 | 3,665,144 | |
| $3.86 | +0.03 | +0.8% | $3.85 | $4.07 | $3.84 | 4,948,347 | |
| $3.83 | -0.18 | -4.5% | $4.02 | $4.059 | $3.78 | 6,370,037 | |
| $4.01 | +0.60 | +17.6% | $3.65 | $4.03 | $3.435 | 6,362,378 | |
| $3.41 | -0.19 | -5.3% | $3.60 | $3.61 | $3.355 | 5,240,000 | |
| $3.60 | -0.07 | -1.9% | $3.70 | $3.82 | $3.50 | 2,653,800 | |
| $3.67 | -0.16 | -4.2% | $3.79 | $3.85 | $3.66 | 4,042,900 | |
| $3.83 | -0.13 | -3.3% | $3.96 | $3.96 | $3.78 | 3,420,500 | |
| $3.96 | -0.06 | -1.5% | $4.02 | $4.055 | $3.95 | 1,926,800 | |
| $4.02 | +0.02 | +0.5% | $3.97 | $4.135 | $3.97 | 2,385,000 | |
| $4.00 | -0.01 | -0.2% | $3.99 | $4.035 | $3.855 | 3,213,900 | |
| $4.01 | -0.02 | -0.5% | $3.99 | $4.175 | $3.91 | 2,449,800 | |
| $4.03 | -0.17 | -4.0% | $4.21 | $4.26 | $4.01 | 2,701,300 | |
| $4.20 | +0.01 | +0.2% | $4.25 | $4.31 | $4.06 | 3,447,900 | |
| $4.19 | +0.07 | +1.7% | $4.21 | $4.265 | $4.105 | 4,019,500 | |
| $4.12 | -0.11 | -2.6% | $4.18 | $4.38 | $4.12 | 3,919,100 | |
| $4.23 | +0.10 | +2.4% | $4.19 | $4.27 | $4.05 | 4,409,400 | |
| $4.13 | +0.12 | +3.0% | $4.00 | $4.237 | $3.94 | 3,706,500 | |
| $4.01 | +0.37 | +10.2% | $3.85 | $4.08 | $3.735 | 5,072,600 | |
| $3.64 | -0.16 | -4.2% | $3.81 | $3.85 | $3.63 | 3,511,300 | |
| $3.80 | -0.07 | -1.8% | $3.85 | $3.87 | $3.725 | 2,022,400 | |
| $3.87 | -0.31 | -7.4% | $4.18 | $4.19 | $3.81 | 2,421,000 | |
| $4.18 | -0.04 | -0.9% | $4.28 | $4.34 | $4.13 | 2,000,200 | |
| $4.22 | -0.01 | -0.2% | $4.27 | $4.358 | $4.12 | 4,183,400 | |
| $4.23 | +0.06 | +1.4% | $4.16 | $4.31 | $4.13 | 4,940,200 | |
| $4.17 | +0.24 | +6.1% | $3.922 | $4.22 | $3.915 | 3,119,700 | |
| $3.93 | +0.01 | +0.3% | $3.91 | $4.00 | $3.875 | 4,513,900 | |
| $3.92 | -0.03 | -0.8% | $3.93 | $3.975 | $3.79 | 2,960,600 | |
| $3.95 | +0.01 | +0.3% | $3.97 | $4.035 | $3.88 | 2,896,000 | |
| $3.94 | -0.20 | -4.8% | $4.195 | $4.195 | $3.92 | 3,935,100 | |
| $4.14 | -0.23 | -5.3% | $4.33 | $4.33 | $4.04 | 4,204,100 | |
| $4.37 | -0.30 | -6.4% | $4.60 | $4.66 | $4.34 | 5,528,400 | |
| $4.67 | -0.20 | -4.1% | $4.76 | $4.785 | $4.64 | 2,139,500 | |
| $4.87 | +0.03 | +0.6% | $4.81 | $4.905 | $4.79 | 1,227,500 | |
| $4.84 | -0.09 | -1.8% | $4.93 | $5.04 | $4.765 | 2,313,300 | |
| $4.93 | +0.04 | +0.8% | $4.90 | $5.075 | $4.78 | 1,842,200 | |
| $4.89 | -0.05 | -1.0% | $4.96 | $5.00 | $4.85 | 1,472,300 | |
| $4.94 | -0.03 | -0.6% | $4.99 | $5.04 | $4.83 | 2,436,800 | |
| $4.97 | -0.28 | -5.3% | $5.18 | $5.205 | $4.945 | 1,618,600 | |
| $5.25 | +0.26 | +5.2% | $5.00 | $5.32 | $4.91 | 3,022,700 | |
| $4.99 | -0.16 | -3.1% | $5.13 | $5.175 | $4.955 | 2,276,000 | |
| $5.15 | +0.09 | +1.8% | $5.13 | $5.225 | $5.085 | 2,941,791 | |
| $5.06 | -0.01 | -0.2% | $5.05 | $5.13 | $4.80 | 3,378,232 | |
| $5.07 | -0.11 | -2.1% | $5.24 | $5.275 | $5.02 | 1,428,500 | |
| $5.18 | -0.32 | -5.8% | $5.41 | $5.465 | $5.105 | 1,669,700 |
- Ticker
- NASDAQ:ANNX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Latest earnings call · Aug 12, 2026
Annexon (NASDAQ:ANNX) Q2 2026 Earnings Call
Replay and transcript
Latest deck · July 2026
Technical Presentation (July 2026)
Technical · 10 slides
Latest news
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Nov 17, 2026
Closed $3.52 (+1.4%) on Nov 18, 2026
Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Nov 9, 2026
Closed $4.21 (-0.5%) on Nov 10, 2026
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
Oct 28, 2026
Closed $4.04 (+7.4%) on Oct 28, 2026
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Sep 24, 2026
Closed $3.80 (-1.8%) on Sep 24, 2026
Annexon to Participate in Upcoming September Investor Conferences
Sep 2, 2026
Closed $4.93 (+0.8%) on Sep 2, 2026
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Aug 12, 2026
Closed $5.33 (-0.2%) on Aug 12, 2026
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Aug 12, 2026
Closed $5.33 (-0.2%) on Aug 12, 2026
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
Aug 10, 2026
Closed $5.34 (-0.9%) on Aug 11, 2026
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Aug 6, 2026
Closed $5.60 (+4.3%) on Aug 6, 2026
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Jul 30, 2026
Closed $5.10 (-3.3%) on Jul 31, 2026
Annexon, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 119 in all · newest Nov 17, 2026 · oldest 2020
- Calls
- 1 call with a replay · 1 with a transcript · latest Aug 12, 2026
- Decks
- 23 decks · latest July 2026
Where Annexon, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ANNX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ANNX | BOATS | United States | USD |
Valuation
Price/book 4.1× against a median of 1.9×: the highest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $423.7M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 1.63
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Annexon, Inc. · NASDAQ:ANNX | US$587.7M | US$423.7M | n/a | n/a | n/a | 4.1× | n/a | 0.3× | 1.63 |
| Olema Pharmaceuticals, Inc. · NASDAQ:OLMA | US$615.0M | US$204.6M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.25 |
| Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637 | US$608.9M | US$483.6M | n/a | 106× | n/a | 2.9× | n/a | 0.4× | n/a |
| Design Therapeutics, Inc. · NASDAQ:DSGN | US$577.6M | US$371.5M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 1.29 |
| Cullinan Therapeutics, Inc. · NASDAQ:CGEM | US$577.1M | US$289.6M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | 1.45 |
| Immix Biopharma, Inc. · NASDAQ:IMMX | US$577.0M | US$241.7M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.60 |
| Entera Bio Ltd. · NASDAQ:ENTX | US$574.8M | US$308.9M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | 0.76 |
| DBV Technologies SA · EURONEXT:DBV | US$571.8M | US$430.7M | n/a | 47.1× | n/a | 3.9× | n/a | 0.1× | n/a |
| Ascletis Pharma, Inc. · HKEX:1672 | US$571.3M | US$232.4M | n/a | 765× | n/a | 1.7× | n/a | 0.0× | n/a |
| 4D Molecular Therapeutics, Inc. · NASDAQ:FDMT | US$565.1M | US$277.8M | n/a | 2.9× | n/a | 1.7× | −208.6% | 0.1× | 1.75 |
| Bicara Therapeutics Inc. · NASDAQ:BCAX | US$560.3M | US$118.8M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.37 |
| Median of the others | US$575.9M | US$283.7M | 76.4× | 1.9× | −208.6% | 0.0× | 1.37 |
Forecasts
6 strong buy · 2 buy · 2 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 17.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.03 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Douglas Love | PRESIDENT & CHIEF EXECUTIVE OFFICER |
| Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER |
| Jamie Dananberg | EVP & CHIEF MEDICAL OFFICER |
| Michael Overdorf | EVP & CHIEF BUSINESS OFFICER |
| Ted Yednock | EVP & CHIEF INNOVATION OFFICER |
| Jung E. Choi | BOARD MEMBER CHIEF BUSINESS AND STRATEGY OFFICER GLOBAL BLOOD THERAPEUTICS |
| Linda Fitzpatrick | CHIEF HUMAN RESOURCES OFFICER |
| Rick Artis | CHIEF SCIENTIFIC OFFICER |
Board
| Director | Role |
|---|---|
| Bettina M. Cockroft | BOARD MEMBER |
| Douglas Love | PRESIDENT & CHIEF EXECUTIVE OFFICER |
| Jung E. Choi | BOARD MEMBER CHIEF BUSINESS AND STRATEGY OFFICER GLOBAL BLOOD THERAPEUTICS |
| Mark Blumenkranz | BOARD MEMBER |
| Will Waddill | LEAD INDEPENDENT DIRECTOR |
| William BJ Jones | BOARD MEMBER |
| William H. Carson | BOARD MEMBER |
Events
Calls
| Call | When | Status |
|---|---|---|
| Annexon (NASDAQ:ANNX) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | −0.5% |
| Q2 2026 | Aug 12, 2026 · Before open | −0.2% |
| Q1 2026 | May 7, 2026 · After close | +3.1% |
| Q4 2025 | Mar 9, 2026 | +17.8% |
| Q3 2025 | Nov 10, 2025 · After close | −0.3% |
| Q2 2025 | Aug 14, 2025 · After close | +2.5% |
| Q1 2025 | May 12, 2025 · Before open | +10.6% |
| Q4 2024 | Mar 24, 2025 · Before open | +12.5% |
| Q3 2024 | Nov 14, 2024 · Before open | −3.4% |
| Q2 2024 | Aug 12, 2024 · Before open | +2.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | +2.5% |
| Q4 2023 | Mar 26, 2024 · After close | +13.5% |
| Q3 2023 | Nov 13, 2023 · Before open | +6.3% |
| Q2 2023 | Aug 7, 2023 · Before open | +2.1% |
| Q1 2023 | May 8, 2023 · After close | +4.6% |
| Q4 2022 | Mar 6, 2023 · Before open | −6.8% |
| Q3 2022 | Nov 3, 2022 · Before open | +1.1% |
| Q2 2022 | Aug 8, 2022 · After close | +2.9% |
| Q1 2022 | May 9, 2022 · After close | +23.1% |
| Q4 2021 | Mar 1, 2022 · After close | −2.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (July 2026) | Technical | 10 slides | July 2026 |
| 44th Annual J.P. Morgan Healthcare Conference 2026 | Conference | 26 slides | Jan 14, 2026 |
| 11th Congress of the European Academy of Neurology 2025 | Conference | 8 slides | June 2025 |
| Technical Presentation (May 2025) | Technical | 4 slides | May 2025 |
| American Academy of Neurology Annual Meeting 2025 | Conference | 14 slides | April 2025 |
| Technical Presentation (June 2024) | Technical | 9 slides | Jun 23, 2024 |
| Technical Presentation (June 2024) | Technical | 35 slides | Jun 4, 2024 |
| Technical Presentation (June 2024) | Technical | 14 slides | June 2024 |
| Technical Presentation (June 2024) | Technical | 13 slides | June 2024 |
| Investor Day (March 2024) | Investor day | 56 slides | Mar 4, 2024 |
All 23 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (February 2024) | Technical | 17 slides | Feb 10, 2024 |
| Technical Presentation (February 2024) | Technical | 23 slides | Feb 3, 2024 |
| Technical Presentation (December 2023) | Technical | 8 slides | Dec 20, 2023 |
| Technical Presentation (December 2023) | Technical | 14 slides | Dec 20, 2023 |
| Technical Presentation (November 2023) | Technical | 17 slides | November 2023 |
| Investor Presentation (January 2023) | Investor deck | 68 slides | Jan 9, 2023 |
| Investor Presentation (July 2022) | Investor deck | 41 slides | Jul 8, 2022 |
| Technical Presentation (March 2022) | Technical | 15 slides | Mar 24, 2022 |
| Technical Presentation (March 2022) | Technical | 11 slides | Mar 10, 2022 |
| 40th Annual J.P. Morgan Healthcare Conference 2022 | Conference | 26 slides | Jan 10, 2022 |
| ASRS 2021 | Conference | 12 slides | October 2021 |
| 2021 Peripheral Nerve Society (PNS) Annual Meeting | Conference | 17 slides | September 2021 |
| Investor Presentation (January 2021) | Investor deck | 33 slides | Jan 11, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Closed: US$86.25M raised · US$2.6 a share · Goldman Sachs & Co. LLC +2 Dealers: Goldman Sachs & Co. LLC (co-lead), TD Cowen (co-lead), Wells Fargo Securities (co-lead) | Nov 14, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Jul 23, 2020.
- Price
- US$17.00 a share
- Shares offered
- 14,750,000 shares of common stock
- Offering size
- US$250.8 million
- Underwriters' option
- Up to 2,212,500 more shares
- Underwriters
- J.P. Morgan, BofA Securities, Cowen · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 18, 2019 |
| Filed publicly | Jul 2, 2020 |
| Amended twice | Newest Jul 23, 2020 |
| Shares registered with an exchange | Jul 21, 2020 |
| Declared effective by the SEC | Jul 23, 2020 |
| Final prospectus, with the price | Jul 24, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 24, 2020 |
| EFFECT · Notice that a registration is effective | Jul 23, 2020 |
| S-1MEF · Registration of more shares for the same offering | Jul 23, 2020 |
| S-1/A · Registration statement, amended | Jul 23, 2020 |
| CERT · Exchange's certificate of listing | Jul 22, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 21, 2020 |
| CORRESP · Letter to the SEC | Jul 21, 2020 |
| CORRESP · Letter to the SEC | Jul 21, 2020 |
| CORRESP · Letter to the SEC | Jul 20, 2020 |
| S-1/A · Registration statement, amended | Jul 20, 2020 |
All 22 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jul 16, 2020 |
| CORRESP · Letter to the SEC | Jul 16, 2020 |
| CORRESP · Letter to the SEC | Jul 14, 2020 |
| S-1 · Registration statement | Jul 2, 2020 |
| DRS/A · Draft registration statement, amended | Feb 26, 2020 |
| DRSLTR · Letter to the SEC with a draft | Dec 6, 2019 |
| DRS/A · Draft registration statement, amended | Dec 6, 2019 |
| UPLOAD · Letter from the SEC | Nov 22, 2019 |
| DRSLTR · Letter to the SEC with a draft | Nov 8, 2019 |
| DRS/A · Draft registration statement, amended | Nov 8, 2019 |
| UPLOAD · Letter from the SEC | Oct 16, 2019 |
| DRS · Draft registration statement | Sep 18, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 24, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 3.69M | 3.45M | 3.27M | 3.31M | 3.41M | 667.0K | 493.0K | 488.0K | 271.0K |
| Gross profit | -3.69M | -3.45M | -3.27M | -3.31M | -3.41M | -667.0K | -493.0K | -488.0K | -271.0K |
| Research and development | 184.7M | 119.4M | 113.8M | 112.5M | 100.1M | 49.3M | 24.5M | 15.5M | 17.9M |
| Selling, general and administrative | 31.7M | 34.6M | 28.0M | 33.1M | 30.6M | 14.2M | 7.99M | 3.62M | 2.62M |
| Operating income | -216.4M | -154.1M | -143.7M | -145.6M | -130.7M | -63.5M | -32.5M | -19.1M | -20.5M |
| Depreciation and amortization | 2.17M | 2.15M | 2.15M | 2.11M | 2.14M | 667.0K | 493.0K | 488.0K | 271.0K |
| EBITDA | -214.2M | -151.9M | -141.6M | -143.5M | -128.6M | -62.8M | -32.0M | -18.7M | -20.2M |
| Interest expense | 3.65M | 2.14M | 0 | 4.66M | 0 | 0 | |||
| Income before tax | -206.7M | -138.2M | 134.2M | 141.9M | 130.3M | -63.4M | -37.2M | -18.3M | -18.7M |
| Income tax | 0 | 0 | 0 | 0 | -2.53M | -667.0K | 4.00K | 1.00K | 1.00K |
| Net income | -206.7M | -138.2M | -134.2M | -141.9M | -130.3M | -63.4M | -37.2M | -18.3M | -18.7M |
| Earnings per share, basic | -1.34 | -1.01 | -1.77 | -2.60 | -3.40 | -4.15 | -88.30 | -1.60 | -0.49 |
| Earnings per share, diluted | -1.34 | -1.01 | -1.77 | -2.60 | -3.40 | -4.15 | -88.30 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 162.1M | 49.5M | 225.1M | 140.0M | 74.8M | 268.6M | 43.9M | 44.2M | 2.97M |
| Short-term investments | 76.3M | 262.5M | 34.6M | 102.6M | 167.9M | 82.6M | |||
| Receivables | 3.00K | 79.0K | 225.0K | 582.0K | |||||
| Inventory | -3.00K | ||||||||
| Current assets | 242.2M | 316.5M | 263.9M | 248.1M | 247.7M | 354.0M | 45.4M | 45.7M | 4.89M |
| Property, plant and equipment | 10.6M | 12.6M | 14.8M | 16.8M | 17.8M | 1.94M | 2.14M | 2.35M | 2.82M |
| Total assets | 277.6M | 350.1M | 297.7M | 285.1M | 287.0M | 355.9M | 49.9M | 48.1M | 7.82M |
| Accounts payable | 14.9M | 10.4M | 5.49M | 7.42M | 11.2M | 3.73M | 2.37M | 1.27M | 1.52M |
| Current liabilities | 42.6M | 30.5M | 17.9M | 22.4M | 21.7M | 10.6M | 4.93M | 3.33M | 2.92M |
| Long-term debt | 0 | ||||||||
| Total debt | 0 | 29.0M | 31.4M | 32.9M | 34.6M | 107.2M | 49.0M | ||
| Total liabilities | 65.9M | 57.0M | 47.1M | 53.9M | 55.1M | 11.7M | 6.37M | 10.3M | 54.0M |
| Shareholders' equity | 211.6M | 293.1M | 250.6M | 231.2M | 231.9M | 344.3M | -100.5M | 37.9M | -46.2M |
| Shares outstanding | 149.4M | 109.4M | 78.4M | 47.7M | 38.6M | 38.2M | 433.7K | 11.5M | 38.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -186.4M | -118.0M | -121.1M | -116.3M | -106.1M | -53.1M | -28.4M | -17.2M | -19.3M |
| Capital spending | -137.0K | -15.0K | -193.0K | -6.53M | -1.65M | -464.0K | -267.0K | -17.0K | -567.0K |
| Free cash flow | -186.5M | -118.0M | -121.3M | -122.8M | -107.8M | -53.6M | -28.6M | -17.2M | -19.8M |
| Cash from investing | 190.1M | -218.8M | 70.7M | 58.4M | -88.2M | -83.2M | -267.0K | -17.0K | -567.0K |
| Cash from financing | 108.9M | 161.2M | 135.5M | 122.9M | 1.79M | 360.9M | 28.4M | 58.5M | 42.0K |
| Dividends paid | -1.86M | -102.5M | |||||||
| Share buybacks | 121.4M | 1.79M | -5.19M | 30.0M | 58.5M | 42.0K | |||
| Change in cash | 112.6M | -175.6M | 85.1M | 65.0M | -192.6M | 224.6M | -244.0K | 41.2M | -19.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 8-K · Current report | Aug 10, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 6, 2026 | Current report | SEC |
| 8-K · Current report | Jul 30, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 14, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 27, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| S-3ASR · Registration statement | Mar 30, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 30, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 17, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 21, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 13, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 23, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 3, 2025 | Offer document | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 13, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 31, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 10, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Dec 19, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 21, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 27, 2024 | Offer document | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 19, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Aug 16, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2024 | Other filings | SEC |
| S-3 · Registration statement | Aug 12, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 5, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
This page holds 200 of 526 filings. Open Filings
Cap table
Built by 6ix from Annexon, Inc.’s releases · as of Nov 14, 2026
- Common shares
- 189,579,134
- Fully diluted
- 189,879,134
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 189,579,134 | |
| Options and RSUs | 300,000 | Nov 14, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · US$3.92 · expire about Nov 2036 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 189,579,134 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Carol G. Gallagher Other companies: TRex Bio, Inc. (Lead Independent Director · Since at least Nov 5, 2026); PMV Pharmaceuticals, Inc. (Director · Since at least Nov 3, 2022); Atara Biotherapeutics, Inc. (Director · Since at least Jun 27, 2019); Certara, Inc. (Director · Jun 15, 2021 – Jun 15, 2021 · Past); Frazier Lifesciences Acquisition Corp (Director · Dec 8, 2020 – Nov 22, 2022 · Past); Metacrine Inc (Director · Sep 15, 2020 – Sep 15, 2020 · Past); Turning Point Therapeutics Inc (Director · Jul 24, 2019 – Aug 17, 2022 · Past); Tempest Therapeutics, Inc. (Director · Jun 20, 2019 – Jun 22, 2020 · Past) | Director · Jul 23, 2020 – Jul 23, 2020 · Past |
| Thomas Wiggans Other companies: Pacira BioSciences, Inc. (Director · Since at least Jun 9, 2026); Jasper Therapeutics, Inc. (Chairman of the Board · Since at least Nov 1, 2023); Pardes Biosciences Inc (Chief Executive Officer, Director · Mar 1, 2022 – Aug 31, 2023 · Past); Forma Therapeutics Holdings Inc (Director · Sep 7, 2020 – Oct 14, 2022 · Past); Somaxon Pharmaceuticals Inc (Director · Jun 11, 2008 – Jul 2, 2012 · Past); Sangamo Therapeutics, Inc. (Director · Jun 4, 2008 – Jun 1, 2011 · Past); Onyx Pharmaceuticals Inc (Director · Aug 29, 2007 – Oct 1, 2013 · Past) | Director · Since at least Jul 23, 2020 |
| William Waddill Other companies: Arrowhead Pharmaceuticals, Inc. (Director · Since at least Dec 20, 2017); Protagonist Therapeutics, Inc. (Independent Director · Since at least Aug 10, 2016); Turnstone Biologics Corp. (Director · Apr 15, 2024 – Jun 3, 2024 · Past); Calithera Biosciences, Inc. (SR. VP & CFO · Oct 1, 2014 – Nov 29, 2016 · Past); OncoMed Pharmaceuticals Inc (SVP & Chief Financial Officer · Jul 17, 2013 – Jul 23, 2013 · Past) | LEAD INDEPENDENT DIRECTOR · Since at least Aug 12, 2021 |
| Muneer A Satter Other companies: Rein Therapeutics, Inc. (See Remarks, Director · Jun 8, 2020 – Jan 8, 2021 · Past); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Jun 18, 2019 · Past); Immunic, Inc. (Director · Apr 16, 2014 – Sep 13, 2018 · Past); Akebia Therapeutics, Inc. (Director · Mar 19, 2014 – Jun 14, 2018 · Past) | Director · Since at least Jul 23, 2020 |
| Jennifer Lew Other companies: Boundless Bio, Inc. (Director · Since at least Mar 27, 2024); Aduro Biotech Inc (Chief Financial Officer · Apr 14, 2015 – May 1, 2019 · Past); Dynavax Technologies Corporation (VP, Finance & PAO · Jan 31, 2012 – Feb 5, 2013 · Past) | EVP & CHIEF FINANCIAL OFFICER · Since at least Jul 23, 2020 |
| Ricky Sun Other companies: Arcutis Biotherapeutics, Inc. (Director · Jan 30, 2020 – Jun 9, 2021 · Past); Savara, Inc. (Director · Dec 24, 2019 – Dec 14, 2023 · Past) | Director · Jul 23, 2020 – Jun 2, 2021 · Past |
| William H. Carson Other companies: Decibel Therapeutics Inc (Director · Jun 2, 2021 – Sep 25, 2023 · Past); Prevail Therapeutics Inc (Director · Sep 9, 2020 – Jan 22, 2021 · Past) | BOARD MEMBER · Since at least Feb 5, 2021 |
| Bettina M. Cockroft Other companies: CNS Pharmaceuticals, Inc. (Director · Since at least Nov 17, 2025) | BOARD MEMBER · Since at least Jun 5, 2025 |
| Jamie Dananberg Other companies: Unity Biotechnology Inc (Chief Medical Officer · May 2, 2018 – Mar 31, 2023 · Past) | EVP & CHIEF MEDICAL OFFICER · Since at least Jul 27, 2023 |
| Dean Richard Artis | EVP & CHIEF SCIENTIFIC OFFICER · Since at least Jan 6, 2023 |
All 20 people
| Person | Seat |
|---|---|
| Douglas Love | PRESIDENT & CHIEF EXECUTIVE OFFICER · Since at least Feb 19, 2026 |
| Jung E. Choi | Director · Since at least Jun 5, 2025 |
| Larry Mattheakis | EVP & Chief Scientific Officer · Sep 30, 2021 – Jul 11, 2022 · Past |
| Linda Fitzpatrick | CHIEF HUMAN RESOURCES OFFICER · Since at least Nov 5, 2026 |
| Lloyd Clark | senior vice president, ophthalmology strategy and innovation · Jun 18, 2025 – Nov 5, 2026 · Past |
| Mark Blumenkranz | Director · Since at least Aug 10, 2026 |
| Michael Overdorf | EVP & CHIEF BUSINESS OFFICER · Since at least Jul 14, 2025 |
| Rick Artis | CHIEF SCIENTIFIC OFFICER · Since at least Nov 5, 2026 |
| Ted Yednock | EVP & CHIEF INNOVATION OFFICER · Since at least Jul 23, 2020 |
| William Jones | BOARD MEMBER · Since at least Jan 10, 2025 |
Log in to ask 6ix AI your own questions about Annexon, Inc.